We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Specific RUNX1 Mutations Cause Different Disease Types

By LabMedica International staff writers
Posted on 28 Jan 2021
Print article
Image: The Cyan ADP flow cytometer (Photo courtesy of Beckman Coulter).
Image: The Cyan ADP flow cytometer (Photo courtesy of Beckman Coulter).
Mutations of the hematopoietic master regulator RUNX1 are associated with acute myeloid leukemia, familial platelet disorder and other hematological malignancies whose phenotypes and prognoses depend upon the class of the RUNX1 mutation.

RUNX1 mutations can occur within the DNA-binding domain (DBD), the transactivation domain (TAD), or are a result of translocations resulting in the generation of fusion proteins. The biochemical behavior of these oncoproteins and their ability to cause unique diseases has been well studied, but the genomic basis of their differential action is unknown.

Cancer and Genomic Scientists at the University of Birmingham (Birmingham, UK;) compared integrated phenotypic, transcriptomic, and genomic data from cells expressing four types of RUNX1 oncoproteins in an inducible fashion during blood development from embryonic stem cells. The team utilized a well-characterized embryonic stem cell (ESC) differentiation system, which recapitulates the different steps of hematopoietic specification of blood cells from haemogenic endothelium (HE) and allows inducible expression of oncoproteins.

The scientists differentiated ESCs were purified by magnetic cell sorting, using biotin-conjugated CD309 antibody, anti-biotin microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Cell populations were identified and sorted and analyzed on a Beckman Coulter analyzer (Beckman Coulter, Pasadena, CA, USA) or sorted on a FACS Aria cell sorter (BD Bioscience, Franklin Lakes, NJ, USA). The team employed other techniques in their study, including CFU assays, Western Blotting, RNA-seq, ATAC-seq and ChIP-seq. Immunocytochemistry slides were visualized using a Zeiss LSM 780 equipped with a Quasar spectral (GaAsP) detection system (Zeiss, Jena, Germany).

The team showed that how each class of mutant RUNX1 deregulates endogenous RUNX1 function by a different mechanism, leading to specific alterations in developmentally controlled transcription factor binding and chromatin programming. The result is distinct perturbations in the trajectories of gene regulatory network changes underlying blood cell development which are consistent with the nature of the final disease phenotype. Some types of RUNX1 mutations directly changed how other genes behaved in blood cells, not all did. In particular, the mutations that are inherited through families do not immediately affect the cells but instead change the roadmap they follow to become other cell types, such as platelets and white blood cells.

Constanze Bonifer, PhD, a Professor of Experimental Haematology, and lead author of the study, said, “The most important results we found came from studying mutations that run in families which predisposes their members to diseases such as Familial Platelet Disorder (FPD) and Acute Myeloid Leukemia (AML). AML is an aggressive cancer of the white blood cells, whereas in FPD, the ability to produce blood clots which is required to stop bleeding is impaired. Prior to this study, it was completely unclear why changes in just one gene cause so many different diseases.”

The team concluded that their results demonstrate that different classes of mutant RUNX1 proteins use unique multifactorial mechanisms to cause disease and so development of novel treatments will require an individual approach. The study was published on January 4, 2021 in the journal Life Science Alliance.

Related Links:
University of Birmingham
Miltenyi Biotec
Beckman Coulter
BD Bioscience
Zeiss


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.